Covered recipient · General Payments record
JAMES E HEUBI
Allopathic & Osteopathic Physicians Pediatrics Pediatric Gastroenterology
This page merges CMS profile IDs 11283882, 465998 — associated profiles published by CMS for the same covered recipient. See the colophon below.
General Payments · PY2018–2021
$115,294.19
- Reported across 147 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2021 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,990.00 | 7 |
By paying entity
PY2021 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SANOFI US SERVICES INC. | $2,490.00 | 1 |
| Alnylam Pharmaceuticals Inc. | $1,150.00 | 1 |
| Retrophin, Inc. | $1,012.50 | 4 |
| Leadiant Biosciences, Inc. | $337.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2021 (7)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc. | $1,150.00 | 08/26/2021 | Consulting Fee | Undisputed | 01/23/2026 | 828514279 | CMS |
| Leadiant Biosciences, Inc. | $337.50 | 05/06/2021 | Consulting Fee | Undisputed | 01/23/2026 | 836181311 | CMS |
| SANOFI US SERVICES INC. | $2,490.00 | 06/03/2021 | Consulting Fee | Undisputed | 01/23/2026 | 843740391 | CMS |
| Travere Therapeutics, Inc. | $337.50 | 02/04/2021 | Consulting Fee | Undisputed | 01/23/2026 | 849778631 | CMS |
| Travere Therapeutics, Inc. | $225.00 | 02/18/2021 | Consulting Fee | Undisputed | 01/23/2026 | 849778627 | CMS |
| Travere Therapeutics, Inc. | $337.50 | 02/18/2021 | Consulting Fee | Undisputed | 01/23/2026 | 849778635 | CMS |
| Travere Therapeutics, Inc. | $112.50 | 03/25/2021 | Consulting Fee | Undisputed | 01/23/2026 | 849778623 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021
- Generated from
- OP_DTL_GNRL_PGYR2021_P01232026_01102026.csv
- Merged CMS profile IDs
- 11283882, 465998
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.